BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. 2008

Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Department of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.

BACKGROUND The aim of this substudy within a prospective, multicenter, placebo-controlled trial was to assess the pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on comedication with mycophenolate mofetil (MMF). METHODS Eighty-two patients aged 3 to 18 years, receiving cyclosporine microemulsion, MMF, corticosteroids, and basiliximab or placebo were investigated. Basiliximab serum concentrations were determined by ELISA, CD25+, and CD122+ T lymphocytes by flow cytometry. RESULTS Basiliximab clearance adjusted to body surface area was significantly (P<0.05) greater in children versus adults, but the relatively higher basiliximab dose given to children yielded similar exposure compared with adolescents. A cross-study comparison revealed that MMF reduced basiliximab clearance and prolonged CD25 saturation duration from approximately 5 weeks in the absence of MMF to 10 weeks in the presence of MMF. Basiliximab led to a marked reduction of CD25+ T-cell fraction during the first 8 to 10 weeks posttransplant, but did not specifically affect CD122+ T cells. The majority of biopsy-proven acute rejection episodes (BPAR) were observed after interleukin (IL) 2-R desaturation, whereas about a quarter of BPARs occurred despite adequate IL2-R blockade. CONCLUSIONS The currently recommended basiliximab dose for pediatric patients, when used with cyclosporine microemulsion and corticosteroids, yielded adequate drug exposure in children and adolescents also under MMF comedication. The observation that about a quarter of BPARs occurred despite adequate IL2-R blockade suggests that another T-cell activation pathway independent of the IL-2/IL-2R pathway is operative, for example, the IL-15 signaling pathway.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis.
January 1998, Transplant international : official journal of the European Society for Organ Transplantation,
Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
March 2005, Transplantation proceedings,
Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
November 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis.
March 1998, International journal of clinical pharmacology and therapeutics,
Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
December 2006, International immunopharmacology,
Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients.
March 2000, Transplantation proceedings,
Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Pharmacokinetics of mycophenolate mofetil in heart transplant recipients.
January 1998, Advances in experimental medicine and biology,
Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients.
August 2001, Pediatric transplantation,
Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen.
January 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Britta Höcker, and John M Kovarik, and Volker Daniel, and Gerhard Opelz, and Henry Fehrenbach, and Martin Holder, and Bernd Hoppe, and Peter Hoyer, and Therese C Jungraithmayr, and Sabine Köpf-Shakib, and Guido F Laube, and Dirk E Müller-Wiefel, and Gisela Offner, and Christian Plank, and Monika Schröder, and Lutz T Weber, and Lothar B Zimmerhackl, and Burkhard Tönshoff
Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients.
December 2009, Journal of clinical pharmacy and therapeutics,
Copied contents to your clipboard!